These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1823 related articles for article (PubMed ID: 30753825)

  • 41. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM; Kottschade LA; Kamath PS; Markovic SN
    Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Fujimura T; Yoshino K; Kato H; Fukushima S; Ishizuki S; Otsuka A; Matsushita S; Amagai R; Muto Y; Yamazaki E; Kambayashi Y; Yahata T; Miyata T; Fujisawa Y; Asano Y
    Br J Dermatol; 2024 Oct; 191(5):691-697. PubMed ID: 38833158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
    Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
    EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.
    Kidwell KM; Postow MA; Panageas KS
    Clin Cancer Res; 2018 Feb; 24(4):730-736. PubMed ID: 28835379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of molecular alterations with immune response in melanoma.
    Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
    Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
    Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
    Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
    [No Abstract]   [Full Text] [Related]  

  • 54. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
    Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
    Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
    van Dijk N; Gil-Jimenez A; Silina K; Hendricksen K; Smit LA; de Feijter JM; van Montfoort ML; van Rooijen C; Peters D; Broeks A; van der Poel HG; Bruining A; Lubeck Y; Sikorska K; Boellaard TN; Kvistborg P; Vis DJ; Hooijberg E; Schumacher TN; van den Broek M; Wessels LFA; Blank CU; van Rhijn BW; van der Heijden MS
    Nat Med; 2020 Dec; 26(12):1839-1844. PubMed ID: 33046870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Carlino MS; Long GV
    Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
    Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
    Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 92.